La vacuna contra el covid-19 desarrollada por AstraZeneca y la Universidad de Oxford tiene una eficacia media del 70%, que llega a 90% con una dosis menor, según ensayos clínicos realizados en el Reino Unido y Brasil, informó el lunes el equipo británico. of Human trials of Oxford University COVID-19 vaccine. (Fuente: AFP)
:quality(75)/cdn.jwplayer.com/v2/media/cUyrwnzB/poster.jpg)
:quality(75)/dvgnzpfv30f28.cloudfront.net/11-23-2020/t_0760f90672c245768f03de132c71220c_name_file_640x360_600_v3_.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/5h1UIiRn/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/XLIWX6IVYFA63APPYFLFMQREXI.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/frIfgMIX/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/s0C6EY3S/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/Fp4txKkv/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/0Iveihj3/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/WJ7ovIRU/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/XLIWX6IVYFA63APPYFLFMQREXI.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/OEOX64ECKFBR5H3UAOANUZ3Q2E.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/t8AjJvjZ/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/FACEUXZLE5DNHFQEAYVP66PHSI.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/cUyrwnzB/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/5h1UIiRn/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/frIfgMIX/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/pWNnuH5w/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/cAs1Uyyl/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/TVKBQS3TEJATNJ2O5DPSM6WRRQ.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/V2ABWUUBNNAEZJ4FSI64SU5O3U.png)
:quality(75)/cdn.jwplayer.com/v2/media/KBOpcpUE/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/koNs9MA2/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/6bLTGi5d/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/KgeU8b6Q/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/a6mwPQ4X/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/X3PAJUVAAFHRXHUYV5TON7UAAY.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/wXUo9jVU/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/nu9nKgwG/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/GCHGHNUMHVAIDBFA2VHOVRIAMY.png)
:quality(75)/cdn.jwplayer.com/v2/media/c0S03whF/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/azLadx4o/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/FQ5XSTUGQ5DI3DYDC3MUSLQL6A.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/9a1H4G0a/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/Xv8iJGpA/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/EXTCEP2GUBC7XBDWQE34RG4BO4.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/DOIUFLVUQ5AJDN2ZVTQQC7KHZ4.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/dXst1BW1/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/JW2JBE7IBZEY5NR2VH4KVTPGZ4.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/42WZKDIDGVA6VKQDF75376W2CA.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/ENCJ6JEIFZHT5E6UXK3KZ5RCUU.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/UZ27WLDNBFBCPCMLG42DQCNJYA.png)